"I'm inspired in discovering and developing potential new drugs to treat serious diseases with unmet medical needs."
I joined Genentech in 2011 as a Scientist after worked 10 years at other pharmaceutical and biotechnology companies. I currently lead the development biotransformation group in support of small molecule drug development. We focus on characterizing the absorption, distribution, metabolism, elimination properties of small molecule drug candidates using state-of-the-art and innovative technologies. I feel incredibly fortunate to have the opportunity working at such a great place with very talented and passionate scientists.
Drug Metab Lett. 2017 Nov 17;11(1):21-28.
Our group focuses on providing key data on determining the rate and route of drug elimination, characterizing the structures of drug metabolites in circulation and excreta, and determining absorption and fraction of metabolism using radiolabeled drugs.
My areas of research interests include the development of novel LC/MS-based techniques for metabolite detection and investigation of biotransformation and bioactivation of xenobiotics.